Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 3,700 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-Small Cell Lung Cancer Clear all

Conditions: Lung Cancer
Interventions: pemetrexed disodium, sorafenib tosylate; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 207
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 124 more

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: paclitaxel poliglumex, pemetrexed; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: afatinib, loperamide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Santa Rosa, California • Orlando, Florida • Port Saint Lucie, Florida + 7 more

Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 611
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more

Conditions: Lung Neoplasms
Interventions: CI 1033; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 44
States / cities: Birmingham, Alabama • Greenbrae, California • San Francisco, California + 30 more

Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: Clovis, California • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
Interventions: efineptakin alfa, Atezolizumab; Drug
Lead sponsor: NeoImmuneTech; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 22
States / cities: Mobile, Alabama • Cerritos, California • Norwich, Connecticut + 19 more

Conditions: Non-small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer Adenocarcinoma
Interventions: grapiprant and pembrolizumab; Drug
Lead sponsor: Arrys Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Stanford, California • Detroit, Michigan • Grand Rapids, Michigan + 2 more

Conditions: Non-Squamous Cell Non-small Cell Lung Cancer
Interventions: Nivolumab, Docetaxel; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 30
States / cities: Scottsdale, Arizona • Duarte, California • San Diego, California + 23 more

Conditions: Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions: CGT4255; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more

Conditions: Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Liver Cancer
Interventions: YE-NEO-001; Biological
Lead sponsor: NantBioScience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Healthy
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 51
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
Interventions: DRP-104, atezolizumab; Drug · Biological
Lead sponsor: Dracen Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more

Conditions: Non-small Cell Lung Cancer
Interventions: Docetaxel and cisplatin, Docetaxel and cisplatin Plus Hypofractionated Radiotherapy; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Addario Lung Cancer Medical Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Carlos, California

Conditions: Lung Cancer
Interventions: antitumor drug screening assay; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 150
States / cities: Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pivanex, Docetaxel; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 5
States / cities: La Verne, California • New Orleans, Louisiana • Brooklyn, New York + 2 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Imprime PGG, MK-3475; Drug
Lead sponsor: Lawrence Feldman, MD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Imatinib mesylate, Paclitaxel; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 70 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Seattle, Washington

Search by objective public record fields.

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)

ADAM-Afatinib Diarrhea Assessment and Management

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)

PDX Models From EGFR Mutant Tumors

Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer